Effect of rifampicin on S-ketamine and s-norketamine plasma concentrations in healthy volunteers after intravenous S-ketamine administration

Anesthesiology

Volumn 114, Issue 6, 2011, Pages 1435-1445

  Noppers, Ingeborg ^a   Olofsen, Erik ^a   Niesters, Marieke ^a   Aarts, Leon ^a   Mooren, René ^a   Dahan, Albert ^a   Kharasch, Evan ^b   Sarton, Elise ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; KETAMINE; NORKETAMINE; RIFAMPICIN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; BEDTIME DOSAGE; CONFERENCE PAPER; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG ELIMINATION; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIMULATION; SINGLE BLIND PROCEDURE;

EID: 79958130479     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e318218a881     Document Type: Conference Paper

References (34)

1. Corssen G: Historical aspects of ketamine: First clinical experience, Status of Ketamine in Anesthesiology. Edited by Dominio EF. Ann Arbor, Michigan, NPP Books, 1990, pp 1-5.
2. Chizh BA: Low dose ketamine: A therapeutic and research tool to explore N-methyl-D-aspartate (NMDA) receptor-mediated plasticity in pain pathways. J Psychopharmacol 2007; 21:259-71. (Pubitemid 46938541)
3. Petrenko AB, Yamakura T, Baba H, Shimoji K: The role of N-methyl-D-aspartate (NMDA) receptors in pain: A review. Anesth Analg 2003; 97:1108-16.
4. Sigtermans M, Dahan A, Mooren R, Bauer M, Kest B, Sarton E, Olofsen E: S(+)-ketamine effect on experimental pain and cardiac output: A population pharmacokinetic-pharmacodynamic modeling study in healthy volunteers. ANESTHESIOLOGY 2009; 111:892-903.
5. Sigtermans M, Noppers I, Sarton E, Bauer M, Mooren R, Olofsen E, Dahan A: An observational study on the effect of S+-ketamine on chronic pain versus experimental acute pain in Complex Regional Pain Syndrome type 1 patients. Eur J Pain 2010; 14:302-7.
6. Sigtermans MJ, van Hilten JJ, Bauer MC, Arbous MS, Marinus J, Sarton EY, Dahan A: Ketamine produces effective and longterm pain relief in patients with Complex Regional Pain Syndrome Type 1. Pain 2009; 145:304-11.
7. Dahan A, Olofsen E, Sigtermans M, Noppers I, Niesters M, Aarts L, Bauer M, Sarton E: Population pharmacokineticpharmacodynamic modeling of ketamine-induced pain relief of chronic pain. Eur J Pain 2011; 15:258-67.
8. Amr YM: Multi-day low dose ketamine infusion as adjuvant to oral gabapentin in spinal cord injury related chronic pain: A prospective, randomized, double blind trial. Pain Physician 2010; 13:245-9.
9. Schwartzman RJ, Alexander GM, Grothusen JR, Paylor T, Reichenberger E, Perreault M: Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: A double-blind placebo controlled study. Pain 2009; 147: 107-15.
10. Adams JD Jr, Baillie TA, Trevor AJ, Castagnoli N Jr: Studies on the biotransformation of ketamine. 1-Identification of metabolites produced in vitro from rat liver microsomal preparations. Biomed Mass Spectrom 1981; 8:527-38. (Pubitemid 12169796)
11. Pedraz JL, Lanao JM, Dominguez-Gil A: Kinetics of ketamine and its metabolites in rabbits with normal and impaired renal function. Eur J Drug Metab Pharmacokinet 1985; 10:33-9. (Pubitemid 15085174)
12. Woolf TF, Adams JD: Biotransformation of ketamine, (Z)-6-hydroxyketamine, and (E)-6-hydroxyketamine by rat, rabbit, and human liver microsomal preparations. Xenobiotica 1987; 17:839-47. (Pubitemid 17105580)
13. Turfus SC, Parkin MC, Cowan DA, Halket JM, Smith NW, Braithwaite RA, Elliot SP, Steventon GB, Kicman AT: Use of human microsomes and deuterated substrates: An alternative approach for the identification of novel metabolites of ketamine by mass spectrometry. Drug Metab Dispos 2009; 37: 1769-78.
14. Hocking G, Visser EJ, Schug SA, Cousins MJ: Ketamine, does life begin at 40? Pain Clinical Updates 2007; 15:1-6.
15. Ebert B, Mikkelsen S, Thorkildsen C, Borgbjerg FM: Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. Eur J Pharmacol 1997; 333:99-104. (Pubitemid 27380456)
16. Holtman JR Jr, Crooks PA, Johnson-Hardy JK, Hojomat M, Kleven M, Wala EP: Effects of norketamine enantiomers in rodent models of persistent pain. Pharmacol Biochem Behav 2008; 90:675-85.
17. Leung LY, Baillie TA: Comparative pharmacology in the rat of ketamine and its two principal metabolites, norketamine and (Z)-6-hydroxynorketamine. J Med Chem 1986; 29:2396-9. (Pubitemid 17182325)
18. Shimoyama M, Shimoyama N, Gorman AL, Elliott KJ, Inturrisi CE: Oral ketamine is antinociceptive in the rat formalin test: Role of the metabolite, norketamine. Pain 1999; 81:85-93. (Pubitemid 29199904)
19. Yanagihara Y, Kariya S, Ohtani M, Uchino K, Aoyama T, Yamamura Y, Iga T: Involvement of CYP2B6 in N-demethylation of ketamine in human liver microsomes. Drug Metab Dis 2001; 29:887-90. (Pubitemid 32488646)
20. Hijazi Y, Boulieu R: Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 2002; 30:853-8. (Pubitemid 34671099)
21. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivistö KT: Pharmacokinetic interactions with rifampicin: Clinical relevance. Clin Pharmacokinet 2003; 42:819-50. (Pubitemid 36995083)
22. Pfenninger EG, Durieux ME, Himmelseher S: Cognitive impairment after small-dose ketamine isomers in comparison to equianalgesic racemic ketamine in human volunteers. ANESTHESIOLOGY 2002; 96:357-66. (Pubitemid 34121746)
23. Holford NHG: A size standard for pharmacokinetics. Clin Pharmacokin 1996; 30:329-32. (Pubitemid 26177179)
24. Beal BL, Sheiner LB, Boeckman AJ, Bauer RJ: NONMEM User's Guide. Icon Development Solutions, Ellicott City, Maryland, 1989-2009.
25. Ihmsen H, Geisslinger G, Schüttler J: Stereoselective pharmacokinetics of ketamine: R(+)-ketamine inhibits the elimination of S(+)-ketamine. Clin Pharmacol Ther 2001; 70: 431-8. (Pubitemid 33135322)
26. Persson J, Hasselström J, Maurset A, Oye I, Svensson JO, Almqvist O, Scheinin H, Gustafsson LL, Almqvist O: Pharmacokinetics and non-analgesic effects of S-and R-ketamines in healthy volunteers with normal and reduced metabolic capacity. Eur J Clin Pharmacol 2002; 57:869-75. (Pubitemid 34185557)
27. Yanagihara Y, Ohtani M, Kariya S, Uchino K, Hiraishi T, Ashizawa N, Aoyama T, Yamamura Y, Yamada Y, Iga T: Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. Biopharm Drug Dispos 2003; 24:37-43. (Pubitemid 36124167)
28. Portmann S, Kwan HY, Theurillat R, Schmitz A, Mevissen M, Thormann W: Enantioselective capillary electrophoresis for identification and characterization of human cytochrome P450 enzymes which metabolize ketamine and norketamine in vitro. J Chromatogr A 2010; 1217:7942-8.
29. Hagelberg NM, Peltoniemi MA, Saari TI, Kurkinen KJ, Laine K, Neuvonen PJ, Olkkola KT: Clarithromycin, a potent inhibitor of CYP3A, greatly increases exposure to oral S-ketamine. Eur J Pain 2010; 14:625-9.
30. Köppel C, Arndt I, Ibe K: Effects of enzyme induction, renal and cardiac function on ketamine plasma kinetics in patients with ketamine long-term analgosedation. Eur J Drug Metab Pharmacokinet 1990; 15:259-63. (Pubitemid 20313127)
31. Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, Fattinger K: Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 2002; 36:164-72. (Pubitemid 34700774)
32. Schüttler J, Stanski DR, White PF, Trevor AJ, Horai Y, Verotta D, Sheiner LB: Pharmacodynamic modeling of the EEG effects of ketamine and its enantiomers in man. J Pharmacokinet Biopharm 1987; 15:241-53. (Pubitemid 18043939)
33. Herd DW, Anderson BJ, Keene NA, Holford NH: Investigating the pharmacodynamics of ketamine in children. Paediatr Anaesth 2008; 18:36-42. (Pubitemid 350264604)
34. Dahan A, Bauer M, Sarton E, Sigtermans M, van Hilten B, Marinus H: Response to Drs. Kapural and Stanton-Hicks. Pain 2010; 149:410-1